Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, 1110 North Stonewall Avenue, Oklahoma City, OK, 73117, USA.
DigiM Solution LLC, 500 West Cummings Park, Suite 3650, Woburn, MA, 01801, USA.
J Nanobiotechnology. 2024 Aug 13;22(1):482. doi: 10.1186/s12951-024-02686-z.
Treatment-induced ototoxicity and accompanying hearing loss are a great concern associated with chemotherapeutic or antibiotic drug regimens. Thus, prophylactic cure or early treatment is desirable by local delivery to the inner ear. In this study, we examined a novel way of intratympanically delivered sustained nanoformulation by using crosslinked hybrid nanoparticle (cHy-NPs) in a thermoresponsive hydrogel i.e. thermogel that can potentially provide a safe and effective treatment towards the treatment-induced or drug-induced ototoxicity. The prophylactic treatment of the ototoxicity can be achieved by using two therapeutic molecules, Flunarizine (FL: T-type calcium channel blocker) and Honokiol (HK: antioxidant) co-encapsulated in the same delivery system. Here we investigated, FL and HK as cytoprotective molecules against cisplatin-induced toxic effects in the House Ear Institute - Organ of Corti 1 (HEI-OC1) cells and in vivo assessments on the neuromast hair cell protection in the zebrafish lateral line. We observed that cytotoxic protective effect can be enhanced by using FL and HK in combination and developing a robust drug delivery formulation. Therefore, FL-and HK-loaded crosslinked hybrid nanoparticles (FL-cHy-NPs and HK-cHy-NPs) were synthesized using a quality-by-design approach (QbD) in which design of experiment-central composite design (DoE-CCD) following the standard least-square model was used for nanoformulation optimization. The physicochemical characterization of FL and HK loaded-NPs suggested the successful synthesis of spherical NPs with polydispersity index < 0.3, drugs encapsulation (> 75%), drugs loading (~ 10%), stability (> 2 months) in the neutral solution, and appropriate cryoprotectant selection. We assessed caspase 3/7 apopototic pathway in vitro that showed significantly reduced signals of caspase 3/7 activation after the FL-cHy-NPs and HK-cHy-NPs (alone or in combination) compared to the CisPt. The final formulation i.e. crosslinked-hybrid-nanoparticle-embedded-in-thermogel was developed by incorporating drug-loaded cHy-NPs in poloxamer-407, poloxamer-188, and carbomer-940-based hydrogel. A combination of artificial intelligence (AI)-based qualitative and quantitative image analysis determined the particle size and distribution throughout the visible segment. The developed formulation was able to release the FL and HK for at least a month. Overall, a highly stable nanoformulation was successfully developed for combating treatment-induced or drug-induced ototoxicity via local administration to the inner ear.
治疗引起的耳毒性和伴随的听力损失是与化疗或抗生素药物治疗方案相关的一个主要关注点。因此,通过局部递送至内耳进行预防性治疗或早期治疗是理想的。在这项研究中,我们研究了一种通过使用交联杂化纳米粒子(cHy-NPs)在热敏水凝胶中的新型经鼓室内持续纳米制剂传递方法,即热凝胶,它有可能为治疗引起或药物引起的耳毒性提供一种安全有效的治疗方法。通过使用两种治疗分子(Flunarizine(FL:T 型钙通道阻滞剂)和Honokiol(HK:抗氧化剂)共同包封在同一递送系统中,可以实现耳毒性的预防性治疗。在这里,我们研究了 FL 和 HK 作为细胞保护分子,以对抗顺铂诱导的 House Ear Institute-Organ of Corti 1(HEI-OC1)细胞中的毒性作用,以及在斑马鱼侧线中对感觉毛细胞保护的体内评估。我们观察到,通过联合使用 FL 和 HK 并开发强大的药物递送配方,可以增强细胞毒性保护作用。因此,使用质量源于设计方法(QbD)合成了载有 FL 和 HK 的交联杂化纳米粒子(FL-cHy-NPs 和 HK-cHy-NPs),其中设计实验-中心复合设计(DoE-CCD)遵循标准最小二乘法模型用于纳米制剂优化。载药纳米粒子的理化特性表明成功合成了具有多分散指数<0.3、药物包封率(>75%)、药物载药量(~10%)、在中性溶液中稳定性(>2 个月)和适当的冷冻保护剂选择的球形纳米粒子。我们评估了体外 caspase 3/7 凋亡途径,结果表明,与 CisPt 相比,FL-cHy-NPs 和 HK-cHy-NPs(单独或联合使用)后 caspase 3/7 激活的信号明显减少。最终制剂即载药 cHy-NPs 嵌入热敏凝胶,是通过将载药 cHy-NPs 掺入泊洛沙姆 407、泊洛沙姆 188 和卡波姆 940 基水凝胶中开发的。基于人工智能(AI)的定性和定量图像分析相结合,确定了整个可见段的粒径和分布。该制剂能够至少释放一个月的 FL 和 HK。总的来说,通过局部给药至内耳,成功开发了一种高度稳定的纳米制剂,用于对抗治疗引起或药物引起的耳毒性。